ALSGD.PA Spineguard

Healthcare Health Care Equipment & Supplies Euronext Paris
0.0868 EUR
Close of Nov 6, 2026
0.0750 0.1680
Market cap
EUR 8.41M
P/E
-
P/B
1.88x
ROE
-109.4%
Dividend yield
-
Fundamental score
0.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALSGD.PA undervalued?

Graham number

The Graham number of Spineguard cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spineguard fundamental analysis

3 of 11 checks passed

ROE 0/2

Negative ROE (-46.97%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-33.46%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 1/2

The stock's PBV ratio (1.35x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

DER 1/2

The stock maintains a fair debt to equity ratio (74%), indicating a reasonable balance between the money it owes and the ownership it possesses.

Revenue Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Net Profit Growth 0/2

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

Assets Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Graham Number 1/1

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Spineguard stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spineguard

SpineGuard SA provides designs, develops, and markets medical devices in the United States, Europe, Latin America, Asia Pacific, and the Middle East. The company offers PediGuard drilling instruments comprising straight, curved, cannulated, PsiFGuard, and threaded PediGuard products. It also provides DSG Connect app that provides surgeons real time visualization of the audio feedback from the DSG Technology during pedicle drillings to ease the signal interpretation. The comp…

Full company profile